Category: Today’s Highlights

Seattle Genetics Deserves Its Stock Rally

Seattle Genetics Deserves Its Stock Rally

Seattle Genetics Stock Rallied Seattle Genetics (SGEN) financial results started with Clay Siegall, Ph.D., President and Chief Executive Officer of the firm stating the following: Seattle Genetics achieved record net sales in the U.S. and Canada for Adcetris, reflecting growth in frontline CD30-expressing peripheral T-cell lymphomas as well as frontline advanced Hodgkin lymphoma.   The Biologics . . . This content is for paid subscribers. Please …
Takeda: Advancing the Potential for Off-the-Shelf, Highly Scalable and Lower Cost CAR T-Cell Therapy for Cancer Treatment.

Takeda: Advancing the Potential for Off-the-Shelf, Highly Scalable and Lower Cost CAR T-Cell Therapy for Cancer Treatment.

CiRA, Takeda & T-CiRA Less than five years ago the Center for iPS Cell Research and Application (CiRA)1 at Kyoto University and Takeda Pharmaceutical (TAK)2 established a research program. Today, Takeda and CiRA announced that induced pluripotent stem cell-derived chimeric antigen receptor (CAR) T-cell therapy (iCART . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Exelixis: Encouraging Results from Cabozantinib Trial and a Good Decision by the Firm

Exelixis: Encouraging Results from Cabozantinib Trial and a Good Decision by the Firm

Exelixis is Expanding Cohorts for COSMIC-021, the Phase 1b Trial for Cabozantinib  From Exelixis (EXEL) we learned about its decision to expand the two original cohorts, and the addition of four new cohorts, to the protocol for COSMIC-021; the phase 1b trial of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) in patients with locally advanced or . . . This content is for paid subscribers. …
Are Illumina’s 2019 Challenges Transitory?

Are Illumina’s 2019 Challenges Transitory?

Illumina Stock Dropped Following Their Preliminary Revenue Announcement Illumina (ILMN) stock dropped 16% following the firm's announcement of preliminary revenue for the second quarter of the fiscal year 2019 and updated its 2019 revenue guidance. According to the firm’s press release its second quarter results were impacted by an approximately $30 million lower revenue than expected; associated with population genomics initiatives, including a sizeable sequencing . …
Small Biotech Firms That Can Become Top-Tier Giants

Small Biotech Firms That Can Become Top-Tier Giants

Small Biotech Firms That Can Become Top-Tier Biotech Giants We Start With... Abeona Therapeutics Abeona Therapeutics (ABEO) is a clinical-stage biopharmaceutical gene and cell therapy company. In September 2016 Abeona acquired an exclusive worldwide license of a next-generation gene therapy AAV capsid portfolio from University of North Carolina at Chapel Hill.  The AIM™ vector system . . . This content is for paid subscribers. Please click here to subscribe …
Atossa Genetics Has Promising News

Atossa Genetics Has Promising News

Atossa Genetics Promising News for Endoxifen Atossa Genetics (ATOS) has promising news from a Phase 2 trial of its topical Endoxifen for mammographic breast density (MBD) reduction.     Preliminary analysis from a recently completed Phase 2 study of Atossa’s proprietary 20mg daily topical Endoxifen has caused a significant and a rapid reduction . . . This content is for paid subscribers. Please click here to subscribe or here to …
Searching for a New Promising Development-Stage Biotech Firm We Found and Picked This One

Searching for a New Promising Development-Stage Biotech Firm We Found and Picked This One

Krystal Biotech Krystal Biotech (KRYS) is a gene therapy firm focused on developing topical intradermal therapeutics for rare dermatological diseases. It developed its a gene therapy product KB103 for the treatment of the broad Dystrophic epidermolysis bullosa (DEB) population, including both recessive and dominant forms of the disease. The vector that introduces the genes into dermal cells is an HSV . . . This content is for …
News From Four Biotech Companies and Several Treatments

News From Four Biotech Companies and Several Treatments

AstraZeneca and Merck PARP Inhibitor Lynparza The AstraZeneca (AZN) and Merck (MRK) PARP inhibitor Lynparza (olaparib) has been granted approval in Europe for first-line maintenance monotherapy . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Nektar Product NKTR-358 Shows Promise in Autoimmune and Chronic Inflammatory Conditions

Nektar Product NKTR-358 Shows Promise in Autoimmune and Chronic Inflammatory Conditions

Nektar Announced Results for NKTR-358  During an oral session at the Annual European Congress of Rheumatology (EULAR) 2019, in Madrid, Nektar Therapeutics (NKTR) announced results of the first-in-human Phase 1a study evaluating single-ascending doses of NKTR-358 for the treatment of autoimmune and other chronic inflammatory conditions.  The . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Gilead Sciences: Improving the Safety and Efficacy of Yescarta® CAR T

Gilead Sciences: Improving the Safety and Efficacy of Yescarta® CAR T

AT ASCO Gilead Sciences and Yescarta® By Acquiring Kite Pharma Gilead Sciences(GILD) gained Kite’s CAR T technology and its FDA approved therapy Yescarta.  At the ASCO 2019 two new analyses were presented from the ZUMA-1 clinical trial of Yescarta®  in adult patients with relapsed or . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
From ASCO: Amgen, Nektar, Sanofi, GRAIL and Others. A Biotech to Keep an Eye on

From ASCO: Amgen, Nektar, Sanofi, GRAIL and Others. A Biotech to Keep an Eye on

What Everyone Wants to Hear from ASCO The American Society of Clinical Oncology (ASCO) meeting is ongoing. What the oncologists, the analysts, the researchers and investors and other interested observers are anxious to hear this year is mostly about the improvements in the immune-oncology approaches. The Oncologists Want to Hear About: Up-to-date information from clinical trials on immunotherapies in order to practice the safest and …
Recent News from Incyte, Merck and Nektar

Recent News from Incyte, Merck and Nektar

Incyte's FDA Approval Based on encouraging data from the REACH1 trial the FDA approved a label expansion of the Incyte (INCY) product Jakafi (ruxolitinib) for graft-versus-host disease (GVHD) in people 12 years and older. The FDA previously granted Jakafi Breakthrough therapy designation and orphan drug status for acute GVHD. GVHD is a condition that might occur after an . . . This content is for paid subscribers. Please …
Array BioPharma: Great News and a Learning Experience

Array BioPharma: Great News and a Learning Experience

Great News for Array BioPharma  Array BioPharma (ARRY) announced positive results from the interim analysis of the Phase 3 BEACON CRC trial. The trial evaluates the combination of: Braftovi® (encorafenib), a BRAF inhibitor, Mektovi® (binimetinib), an MEK inhibitor, and Erbitux® (cetuximab), an anti-EGFR antibody (BRAFTOVI Triplet), in patients with 
Another Late-Stage Firm with Impressive Technology and Promising Products

Another Late-Stage Firm with Impressive Technology and Promising Products

About Iovance Biotherapeutics Iovance Biotherapeutics (IOVA) is a late-stage biotechnology company developing novel cancer immunotherapies based on its tumor-infiltrating lymphocyte (TIL) technology. Iovance announced promising updates from ongoing clinical trials in advanced cervical cancer and advanced melanoma. The data will be presented at the 55th Annual . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Regeneron: Why the FDA Approval of EYLEA for Diabetic Retinopathy is Extremely Important.

Regeneron: Why the FDA Approval of EYLEA for Diabetic Retinopathy is Extremely Important.

The FDA Approval of Regeneron's EYLEA Is Important The PANORAMA Trial of EYLEA for Diabetic Retinopathy The United States Food and Drug Administration (FDA) has approved Regeneron’s (REGN) product EYLEA® (aflibercept) Injection for all stages of diabetic retinopathy. This approval is important. The data demonstrated from the PANORAMA trial showed EYLEA’s . . . This content is for paid subscribers. Please click here to subscribe or here to log in.